GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Madrigal Pharmaceuticals Inc (NAS:MDGL) » Definitions » Cyclically Adjusted PB Ratio

MDGL (Madrigal Pharmaceuticals) Cyclically Adjusted PB Ratio : 13.57 (As of May. 29, 2025)


View and export this data going back to 2007. Start your Free Trial

What is Madrigal Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2025-05-29), Madrigal Pharmaceuticals's current share price is $269.93. Madrigal Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was $19.89. Madrigal Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 13.57.

The historical rank and industry rank for Madrigal Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

MDGL' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 10.88   Med: 15.5   Max: 18.3
Current: 13.62

During the past years, Madrigal Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 18.30. The lowest was 10.88. And the median was 15.50.

MDGL's Cyclically Adjusted PB Ratio is ranked worse than
92.09% of 670 companies
in the Biotechnology industry
Industry Median: 1.485 vs MDGL: 13.62

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Madrigal Pharmaceuticals's adjusted book value per share data for the three months ended in Mar. 2025 was $32.028. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $19.89 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Madrigal Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Madrigal Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Madrigal Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Madrigal Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.84 4.27 15.36 12.87 15.96

Madrigal Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.18 14.67 11.08 15.96 16.65

Competitive Comparison of Madrigal Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Madrigal Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Madrigal Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Madrigal Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Madrigal Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


;
;

Madrigal Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Madrigal Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=269.93/19.89
=13.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Madrigal Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Madrigal Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=32.028/134.9266*134.9266
=32.028

Current CPI (Mar. 2025) = 134.9266.

Madrigal Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201506 18.006 100.684 24.130
201509 15.334 100.392 20.609
201512 -12.424 99.792 -16.798
201603 11.260 100.470 15.122
201606 10.560 101.688 14.012
201609 3.249 101.861 4.304
201612 3.046 101.863 4.035
201703 2.832 102.862 3.715
201706 4.932 103.349 6.439
201709 4.346 104.136 5.631
201712 12.810 104.011 16.618
201803 12.433 105.290 15.933
201806 31.636 106.317 40.149
201809 31.372 106.507 39.743
201812 30.955 105.998 39.403
201903 30.389 107.251 38.231
201906 29.624 108.070 36.986
201909 28.540 108.329 35.547
201912 26.999 108.420 33.600
202003 24.984 108.902 30.955
202006 22.212 108.767 27.554
202009 18.732 109.815 23.016
202012 15.474 109.897 18.998
202103 16.221 111.754 19.584
202106 16.304 114.631 19.191
202109 13.931 115.734 16.241
202112 11.466 117.630 13.152
202203 8.522 121.301 9.479
202206 4.884 125.017 5.271
202209 0.624 125.227 0.672
202212 10.904 125.222 11.749
202303 8.212 127.348 8.701
202306 5.607 128.729 5.877
202309 1.203 129.860 1.250
202312 20.394 129.419 21.262
202403 41.129 131.776 42.112
202406 39.497 132.554 40.204
202409 35.640 133.029 36.148
202412 34.282 133.157 34.738
202503 32.028 134.927 32.028

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Madrigal Pharmaceuticals  (NAS:MDGL) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Madrigal Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Madrigal Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Madrigal Pharmaceuticals Business Description

Traded in Other Exchanges
Address
200 Barr Harbor Drive, Suite 200, Four Tower Bridge, West Conshohocken, PA, USA, 19428
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
Executives
Fred B Craves director, 10 percent owner 750 BATTERY ST, STE 600, SAN FRANCISCO CA 94111
Robert E. Waltermire officer: Senior VP, Chief Pharma Dev. FOUR TOWER BRIDGE, 200 BARR HARBOR DRIVE, SUITE 200, WEST CONSHOHOCKEN PA 19428
James M Daly director INCYTE CORPORATION EXPERIMENTAL STATION, RTE 141 & HENRY CLAY RD. BLDG E336, WILMINGTON DE 19880
Kenneth Bate director C/O MILLENNIUM PHARMACEUTICALS INC, 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
William John Sibold director, officer: President and CEO C/O MADRIGAL PHARMACEUTICALS, INC., FOUR, TOWER BRIDGE, 200 BARR HARBOR DR STE 200, WEST CONSHOHOCKEN PA 19428
Rebecca Taub director, officer: Chief Medical Officer, EVP R&D 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Richard S Levy director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Paul A Friedman director, officer: Chief Executive Officer C/O INCYTE CORPORATION, 1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Baker Bros. Advisors Lp director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Brian Joseph Lynch officer: SVP and General Counsel 480 MORRIS ROAD, BLUE BELL PA 19422
Felix Baker director BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Raymond Cheong director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Julian Baker director BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667, director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014

Madrigal Pharmaceuticals Headlines

From GuruFocus